Study #2018-0458
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Ad
MD Anderson Study Status
Not Accepting
Treatment Agent
sotorasib, Anti PD-1/L1, Midazolam
Description
Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
KRAS p.G12C Mutant Advanced Solid Tumors
Study phase:
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-563-0193
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.